🏛️ Verified NIH Record • Updated 2026-04-12
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML (NCT06561152)
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Stanford University
🩺 Plain-English Summary (8th-Grade Level)
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
Who can join: Review the eligibility criteria below.
Location: Stanford University — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Stanford University — Palo Alto, California
📞 Contact the Study Coordinator
Phone: (650) 721-2443
Email: wooin@stanford.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Refractory Acute Myeloid Leukemia
- CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS — Cleveland, Ohio
- A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia — Basking Ridge, New Jersey
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia — San Diego, California
Explore by condition: All Refractory Acute Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.